Biomarker Core

Biomarkers of Cognitive Impairment

The biomarker core is integrated with the other ADC cores, and we have added blood biomarker measures to our monthly clinical-pathological consensus conferences so that we can begin to understand what blood measures may indicate with respect to brain pathology and clinical symptoms. The biomarker core aims to develop blood-based biomarkers, and imaging based biomarkers, to discriminate the underlying cause of an individual’s cognitive impairment so that we can begin to move in a precision medicine direction for the treatment of cognitive impairment and dementia. 

Important discoveries by the core to date include:

1. Development of accurate brain imaging methods to identify early stages of cerebrovascular disease;
2. Linking specific cerebrospinal fluid and plasma biomarkers with specific brain imaging patterns;
3. White matter hyperintensities do not behave the same way in every individual. We have found that they can grow over time in some individuals, remain stable, or in some cases even regress; 
4. Plasma biomarkers of Alzheimer’s disease are emerging as promising alternatives to costly imaging to determine brain amyloid load, but more testing needs to be done and is currently being performed in the core; and, 
5. There are inflammatory biomarkers that appear to be associated with cerebrovascular disease. 

Goals of the Core

The overall goal of the UK-Alzheimer's Disease Center (ADC) biomarker core is to perform state-of-the-art neuroimaging and fluid assessments to develop novel biomarkers for diagnosis and precision medicine. A biomarker describes a measure that is indicative of a specific pathological process. The biomarker core was added to the ADC in 2018 and the primary goals of the core are to: